Grifols (GRF) Stock Overview
Engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 1/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
GRF Community Fair Values
Create NarrativeSee what 56 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Grifols, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €8.95 |
| 52 Week High | €13.70 |
| 52 Week Low | €8.43 |
| Beta | 1.17 |
| 1 Month Change | -5.49% |
| 3 Month Change | -0.13% |
| 1 Year Change | -10.00% |
| 3 Year Change | -20.78% |
| 5 Year Change | -60.56% |
| Change since IPO | 240.88% |
Recent News & Updates
GRF: New Bleeding Disorder Therapy And Margin Focus Will Drive Future Upside
Analysts have trimmed their price target on Grifols by €0.25, reflecting slightly lower fair value assumptions and updated views on discount rates, growth, and profitability, in line with recent Street research that reduced targets by about €1.00. Analyst Commentary Recent research on Grifols points to a more cautious stance on valuation, with price targets adjusted to reflect updated assumptions on growth, profitability, and discount rates.Grifols (BME:GRF) Stock Could Be 37.9% Undervalued After FESILTY Launch
Grifols (BME:GRF) has drawn fresh attention after launching FESILTY in the U.S., a fibrinogen concentrate for acute bleeding in patients with congenital fibrinogen deficiency, following recent FDA approval and supporting clinical data. See our latest analysis for Grifols. For investors, the FESILTY launch comes at a time when Grifols’ 1 day share price return of 1.04% and 7 day share price return of 0.75% sit against a year to date share price return that has declined 18.70%, while the 1 year...Recent updates
GRF: New Bleeding Disorder Therapy And Margin Focus Will Drive Future Upside
Analysts have trimmed their price target on Grifols by €0.25, reflecting slightly lower fair value assumptions and updated views on discount rates, growth, and profitability, in line with recent Street research that reduced targets by about €1.00. Analyst Commentary Recent research on Grifols points to a more cautious stance on valuation, with price targets adjusted to reflect updated assumptions on growth, profitability, and discount rates.Grifols (BME:GRF) Stock Could Be 37.9% Undervalued After FESILTY Launch
Grifols (BME:GRF) has drawn fresh attention after launching FESILTY in the U.S., a fibrinogen concentrate for acute bleeding in patients with congenital fibrinogen deficiency, following recent FDA approval and supporting clinical data. See our latest analysis for Grifols. For investors, the FESILTY launch comes at a time when Grifols’ 1 day share price return of 1.04% and 7 day share price return of 0.75% sit against a year to date share price return that has declined 18.70%, while the 1 year...
GRF: Margin Protection And Biopharma Strength Will Support Future Upside
Analysts have reduced their price target on Grifols to €10 from €11, reflecting updated views on revenue growth and margins, as well as recent resets in Street forecasts following concerns around albumin and alpha-1 trends. Analyst Commentary Recent Street research reflects a more cautious stance on Grifols, with price targets reset to €10 and €11 and ratings aligned with a more neutral view.GRF: Margin Protection And US Biopharma IPO Plans Will Drive Future Upside
Analysts have trimmed their fair value estimate for Grifols from €15.08 to €14.65. This reflects recent cuts to Street price targets and concerns around slower albumin and alpha-1 volume growth that have led banks such as Deutsche Bank and Morgan Stanley to lower their expectations.GRF: Higher Required Returns Will Still Support Upside From Current Pricing
Analysts have trimmed their price targets on Grifols, with recent research such as the move from €15.00 to €13.50 supporting a modest reduction in our fair value estimate from €15.20 to about €15.08. They are factoring in slightly softer growth and margin assumptions alongside a higher expected discount rate, partly offset by a higher future P/E ratio.GRF: Execution On Profitability Reset And Higher P/E Will Unlock Upside
Analysts have nudged their fair value estimate for Grifols slightly lower to €21.72 from €21.78, reflecting reduced revenue growth and profit margin assumptions, alongside a higher future P/E, in line with recent Street moves such as Barclays trimming its price target to €13.50 from €15.00. Analyst Commentary Bullish analysts appear to be treating the latest target cut as more of a valuation reset than a shift in long term conviction, with the rating held at Overweight even as the price objective moves to €13.50 from €15.00.GRF: Higher Required Returns Will Still Support Attractive Future Earnings Multiple
Analysts have trimmed their valuation outlook for Grifols, reducing the implied price target from €15.20 to €15.03 as they factor in a higher discount rate and a slightly richer future P/E assumption, while keeping revenue growth and profit margin expectations broadly unchanged. Valuation Changes Fair Value: Held broadly steady at €15.20, with only a marginal adjustment to the implied price target in the updated model.GRF: Higher Discount Rate Will Still Support Attractive Future Upside Potential
Analysts have modestly reduced their price target on Grifols from approximately 23.00 dollars to 21.78 dollars, citing a higher perceived discount rate that more than offsets slightly stronger long term revenue growth and margin assumptions, along with a lower future price to earnings multiple. What's in the News Grifols has scheduled a Board meeting on September 25, 2025, to approve the creation of a Strategy Committee with an advisory role focused on strategic initiatives and developments, as defined in the Regulations of the Internal Functioning of the Board of Directors and the committee's own regulations (company filing).GRF: Upcoming Strategy Committee Will Support Improved Profit Margins Ahead
Analysts have slightly lowered their price target for Grifols from $15.45 to $15.20, citing minor adjustments to growth projections and profit expectations. What's in the News Grifols, S.A. is holding a Board Meeting on September 25, 2025, to establish a Strategy Committee with an advisory role focused on strategic initiatives and developments (Key Developments).GRF: Rising Margins and Board Initiatives Will Drive Future Performance
Analysts have lowered their price target for Grifols from $16.48 to $15.45, citing modestly reduced revenue growth expectations and a lower future price-to-earnings multiple. This comes despite slightly improved profit margins and a more favorable discount rate.
Biopharma Innovations And Tactical Strengths Propel Future Profitability And Market Expansion
Grifols' focus on innovation and new product development is poised to drive future revenue growth and market expansion.Shareholder Returns
| GRF | ES Biotechs | ES Market | |
|---|---|---|---|
| 7D | -1.1% | 5.3% | 1.3% |
| 1Y | -10.0% | 40.5% | 33.3% |
Return vs Industry: GRF underperformed the Spanish Biotechs industry which returned 40.1% over the past year.
Return vs Market: GRF underperformed the Spanish Market which returned 35.2% over the past year.
Price Volatility
| GRF volatility | |
|---|---|
| GRF Average Weekly Movement | 4.3% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in ES Market | 6.5% |
| 10% least volatile stocks in ES Market | 0.9% |
Stable Share Price: GRF has not had significant price volatility in the past 3 months compared to the Spanish market.
Volatility Over Time: GRF's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1909 | 25,000 | Nacho Abia Buenache | www.grifols.com |
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services.
Grifols, S.A. Fundamentals Summary
| GRF fundamental statistics | |
|---|---|
| Market cap | €5.49b |
| Earnings (TTM) | €415.00m |
| Revenue (TTM) | €7.44b |
Is GRF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRF income statement (TTM) | |
|---|---|
| Revenue | €7.44b |
| Cost of Revenue | €4.58b |
| Gross Profit | €2.85b |
| Other Expenses | €2.44b |
| Earnings | €415.00m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.61 |
| Gross Margin | 38.36% |
| Net Profit Margin | 5.58% |
| Debt/Equity Ratio | 109.9% |
How did GRF perform over the long term?
See historical performance and comparisonDividends
Does GRF pay a reliable dividends?
See GRF dividend history and benchmarks| Grifols dividend dates | |
|---|---|
| Ex Dividend Date | Jun 30 2026 |
| Dividend Pay Date | Jul 02 2026 |
| Days until Ex dividend | 5 days |
| Days until Dividend pay date | 7 days |
Does GRF pay a reliable dividends?
See GRF dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/23 13:02 |
| End of Day Share Price | 2026/06/23 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Grifols, S.A. is covered by 29 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Banco de Sabadell. S.A. |
| Luis Arredondo | Banco de Sabadell. S.A. |
| Jaime Escribano | Banco Santander |